PhaseBio Pharmaceuticals Past Performance
How has PhaseBio Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PHAS is currently unprofitable.
Growing Profit Margin: PHAS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PHAS is unprofitable, and losses have increased over the past 5 years at a rate of 46.4% per year.
Accelerating Growth: Unable to compare PHAS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PHAS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: PHAS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.